Complementary DNAs encoding the precursor of human hepatic mitochondrial acetoacetyl-CoA thiolase (T2) (EC 2.3.1.9) were cloned and sequenced. The cDNA inserts in these clones were 1,518 bases in length when overlapped, and encoded the 427-amino acid precursor of this enzyme (45,199 mol wt). This amino acid sequence included a 33-residue leader peptide moiety and a 394-amino acid subunit of the mature enzyme (41,385 mol wt). The T2 gene expression in fibroblasts from four patients with 3-ketothiolase deficiency was analyzed by Northern blotting. The T2 mRNA in all four cell lines had the same 1.7 kb as that of the control. However, the amounts of T2 mRNA differed: the content was reduced in two cell lines (cases 1 and 3), whereas it was within a normal range in others (cases 2 and 4). Pulse labeling followed by subcellular fractionation revealed that the T2 proteins in the fibroblasts from these patients are present in the mitochondria. These results suggest that different mechanisms are involved in the enzyme defects in the four patients. (J. Clin.
Introduction

3-Ketothiolase deficiency (3KTD'
20375) is an inborn error of isoleucine and ketone body catabolism. It is characterized by intermittent ketoacidosis episodes and urinary excretion of organic acids such as 2-methyl-3-hydroxybutyrate, 2-methyl-acetoacetate, and tiglylglycine. Since Daum et al. (1) reported this disorder in 1971 , over 10 cases have been documented (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . Mammalian tissues have at least four thiolases; mitochondrial 3-ketoacyl-CoA thiolase (T 1), acetoacetyl-CoA thiolase (T2), peroxisomal 3-ketoacylCoA thiolase (PT), and cytosolic acetoacetyl-CoA thiolase (CT) (13) (14) (15) . The etiology of 3KTD has been attributed to a defect in T2 because K+ activation of acetoacetyl-CoA thiolase, a characteristic feature of T2 (7), is absent in tissue from patients with this disorder (6, 9, 10, 12) . T2 alone seems to be responsible for the cleavage of 2-methylacetoacetyl-CoA, an intermediate of isoleucine catabolism (7, 16) . The term "3KTD" is commonly used for T2 deficiency, although deficiencies of PT and CT have also been reported (17, 18) .
Previously, we reported that 3KTD in a patient was due to a defect in the T2 biosynthesis (19) . Subsequently, we demonstrated using the pulse-chase experiments that, in the fibroblasts from five 3KTD patients (including the first one), the T2 proteins of these patients were synthesized but they differed in stability and in mobility in SDS-PAGE (20, 21) , providing evidence for heterogeneity in the molecular defects (21). To better understand 3KTD at the molecular level, we first cloned cDNA for rat T2 (22) .
We now report the molecular cloning and nucleotide sequence of cDNA for human T2 and the gene expression of T2 in fibroblasts from four patients with 3KTD.
Methods
Patients. Case 1 is a Japanese boy who presented with episodic ketoacidosis (10) and case 2 is a Spanish girl who repeatedly experienced severe ketoacidosis attacks (9) . Case 3 is a Laotian boy who was well developed but had several episodes of ketoacidosis (9) . Case 4 is a boy with normal development, despite episodic ketoacidosis. His father is also a patient but without symptoms of this deficiency (7) . The diagnosis of 3KTD in the four patients was based on the results of urinary organic acid analyses by gas chromatography-mass spectrometry, and of the enzyme assay of their fibroblasts (7, 9, 10) . The four cell lines were well characterized, at the protein level. The amount, biosynthesis, and degradation of T2 protein in the fibroblasts were analyzed by immunoblot and pulse-chase experiments (19) (20) (21) . These results are listed later in Table II Screening of the cDNA library. The Xgtl 1 cDNA library constructed from human hepatic poly(A)RNA with random primers was kindly provided by Dr. M. Mori. The cDNA library was screened with the probe, RT2-6, a full-length cDNA of the rat T2 (22), using the plaque hybridization method (23) .
Subcloning and DNA sequencing. Inserts of cDNA clones were subcloned to plasma vectors pTZ (U. S. Biochemical Corp., Cleveland, OH) or pHSG (Takara Shuzo, Kyoto, Japan). Appropriate fragments for sequencing were obtained by treatment with nuclease Ba131 or restriction endonucleases (Takara Shuzo). DNA sequences were analyzed on the double-strand plasmid DNA by the dideoxy chain termination method with the Klenow fragment (Takara Shuzo) or Sequenase (U. S. Biochemical Corp.) (24, 25) .
Northern blot analysis. Skin fibroblasts were grown in Eagle's minimum essential medium containing 10% fetal calf serum. The cells were harvested 3-4 d after achieving confluency. Total RNA was pre-pared from fibroblasts by acid guanidium thiocyanate-phenol-chloroform extraction (26). Total RNA was denatured in formamide/formaldehyde and electrophoresed in a 1.0% agarose gel containing formaldehyde (27) . RNA was transferred to a sheet ofHybond-N (Amersham Corp., Arlington Heights, IL) by capillary blotting. Prehybridization, hybridization, and washing were carried out using the conditions recommended in the manufacturer's protocol. The insert of HT2-3 (see Fig. 1 ) was used as a probe. In order to provide standards for the amount ofapplied RNAs, the same membrane was rehybridized with a ,B-actin probe (28). Messenger RNA was quantitated by scanning densitometry of the autoradiograms.
Protein analyses. The human enzyme was purified from an postmortem liver using the procedure previously used for the purification of rat liver enzyme (22) . Two peaks of T2 activity on the phosphocellulose column chromatography, isoenzymes A and B (15, 29) , were separately purified. The purified proteins were S-carboxymethylated. 
Results
Isolation of cDNA clones for human T2. The Xgt 11 cDNA library was screened using as a probe RT2-6 (22), a full-length cDNA for the rat T2. After screening 4.0 X 105 recombinant plaques, 13 independent positive clones were obtained (Fig. 1) . All cDNA inserts were subcloned to plasmid vectors and were sequenced for the entire regions of inserts.
Sequence analysis ofthe cDNA. The nucleotide sequence of the cDNA for the human T2 is summarized in Fig. 2 When the deduced amino acid sequences of human and rat T2 were compared (Fig. 3) , these sequences share 84% of identical residues. In contrast, sequence homologies of human T2 to other rat thiolases, TI and PT (31, 32) 1 MAALA-VLH--GVVRRPLLRGLLQEVRCLGRSYASKPTLNDVVIVSATRTPIGSFLGSLA ** ** * **** * ** * ***i ***** ****************** HT2: 1 MAVLAALLRSGARSRSPLLRRLVQEIRYVERSYVSKPTLKEVVIVSATRTPIGSFLGSLS RT2: 58 SQPATKLGTIAIQGAIEKAGIPKEEVKEVYMGNVIQGGEGQAPTRQATLGAGLPIATPCT ****** ******************* ***** ************ ******* **** HT2: 61 LLPATKLGSIAIQGAIEKAGIPKEEVKEAYMGNVLQGGEGQAPTRQAVLGAGLPISTPCT RT2: 118 TVNKVCASGMKAIMMASQSLMCGHQDVMVAGGMESMSNVPYVMSRGATPYGGVKLEDLIV * ***************************************** ** ************* HT2: 121 TINKVCASGMKAIMMASQSLMCGHQDVMVAGGMESMSNVPYVMNRGSTPYGGVKLEDLIV RT2: 178 KDGLTDVYNKIHMGNCAENTAKKLSISREEQDKYAIGSYTRSKEAWDAGKFANEIMPITI ************** .********* * * *** *** ****** ** **** ** * * HT2: 181 KDGLTDVYNKIHMGSCAENTAKKLNIARNEQDAYAINSYTRSKAAWEAGKFGNEVIPVTV RT2: 238 SVKGKPDVVVKEDEEYKRVDFSKVPKLKTVFQKENGTVTAANASTLNDGAAAVVLMTAEA **** *********************************************** ***** * HT2: 241 TVKGQPDVVVKEDEEYKRVDFSKVPKLKTVFQKENGTVTAANASTLNDGAAALVLMTADA RT2: 298 AQRLKVKPLARIAAFADAAVDPIDFPLAPAYAVPKVLKYAGLKKEDIAMWEVNEAFSVVV * ** * ***** ******* ***** ** ** *** ***************** ** HT2: 301 AKRLNVTPLARIVAFADAAVEPIDFPIAPVYAASMVLKDVGLKKEDIAMWEVNEAFSLVV RT2:
HT2:
358 LANIKMLEIDPQKVNVHGGAVSLGHPIGMSGARIVVHLAHALKQGEFGLASICNGGGGAS *************** ****************** ** ******* ************* 361 LANIKMLEIDPQKVNINGGAVSLGHPIGMSGARIVGHLTHALKQGEYGLASICNGGGGAS RT2: 418 AVLIEKL * ** ** HT2: 421 AMLIQKL indicated by underlining). Amino acid compositions of the two isoenzymes were also indistinguishable. The composition was also compatible with that calculated from the deduced sequence (Table I) .
Expression ofthe thiolase gene in fibroblasts. Expression of T2 gene in fibroblasts from the controls and from the patients was analyzed by Northern blotting, using the cDNA insert of HT2-3 as a probe (Fig. 4 A) Fig. 4 B. Pa- Subcellular fractionation after pulse labeling of the fibroblasts. Subcellular fractionation was then done to determine whether or not the pulse-labeled T2 ofthe fibroblasts from the patients were transported into the mitochondria or were degraded in cytosol. The labeled T2 was recovered in the particle fraction, whereas lactate dehydrogenase, a cytosolic enzyme, was present in the cytosol, without exception (Fig. 5) . The T2 proteins can therefore be translocated into an organelle, presumably into the mitochondria.
Discussion
The cDNA for human T2 which we cloned was 1,518 bp in length, including a 1,281-base open reading frame encoding the entire precursor for this enzyme. This cDNA will serve as a pertinent tool for further studies on the molecular basis of heterogeneity in 3KTD. It has been proposed that there are two isoenzymes of T2 since this enzyme was separated into two main peaks on phosphocellulose column chromatography during the process of purification (13, 29) . We indeed confirmed the presence oftwo peaks of T2 activity. The existence of these isoenzymes might cause confusion in the study of 3KTD. However, Huth (33) has proposed that these isoenzymes are produced by post (33) .
We examined by Northern blotting the expression of T2 mRNA in fibroblasts from four patients who have been well characterized at the protein level (19) (20) (21) pulse-labeled T2 proteins could be detected after a 72-h chase, in either case (21). However, Northern blot analysis revealed that they differed in expression of T2 mRNA. In case 1, the T2 mRNA was moderately decreased. The pulse-labeled T2 had a slower electrophoretic mobility than did the normal mature T2 subunit. The synthesized T2 was unstable. Fractionation of fibroblasts after pulse labeling revealed that the variant T2 protein is translocated into mitochondria and degraded there. In case 2, the amount of T2 mRNA was within a normal range; however, a smaller amount of normal-sized T2 protein was detected in the mitochondrial C 1 2 3 4 IPs~-l P I S P IS I I PI-'SlPIS' . Subcellular fractionation after pulse labeling. The pulse-labeled fibroblasts were fractionated into supernatant (cytosolic fraction, S) and pellets (particle fraction, P), as described in Methods. Each fraction was subjected to immunoprecipitation with anti-mitochondrial acetoacetyl-CoA thiolase (T2) antibody and anti-lactate dehydrogenase (LDH) antibody followed by SDS-PAGE and fluorography. C, control fibroblasts; 1-4, the cell lines of cases 1-4, respectively. Arrowheads indicate the bands for T2 or LDH.
fraction, and was unstable. Hence the mutation of T2 gene must be located in the region coding for the mature T2 protein. In case 3, the amount of T2 mRNA was markedly decreased, and the amount ofT2 protein detected was also small. The mobility in SDS-PAGE and stability ofthe T2 were indistinguishable from those of controls. The cause of an enzyme defect in this patient seems to be a gene mutation affecting the splicing, or inefficient transcription. Middleton et al. (9) reported that some residual T2 activity, -7% ofthe control, was detected in fibroblasts from this patient. Taken together, the T2 protein in case 3 might be functional. In case 4, the amount ofT2 mRNA was within a normal range, and the pulse-labeled T2 was normal in size but unstable. T2 protein was smaller in amount than that ofthe controls and degraded considerably at a 72-h chase. A point mutation in the protein coding region may be considered as the cause of the enzyme defect in case 4. The mutation sites in the coding region in cases 2 and 4 patients presumably differ because the mutant protein in case 2 degraded more rapidly than did that from case 4. Thus, the molecular basis ofthe disease appears to be different in all four patients. 
